Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence in investing [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks with the highest potential to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow to highlight attractive investment opportunities [3] Growth Score - The Growth Style Score assesses a company's financial health and future prospects by examining projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth potential [4] Momentum Score - The Momentum Style Score is based on price trends and earnings outlook changes, utilizing factors like one-week price change and monthly earnings estimate changes to identify favorable investment timing [5] VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, providing a comprehensive indicator for investors seeking stocks with the best overall potential [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.9% since 1988, significantly outperforming the S&P 500 [7][8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while ensuring that 3 (Hold) ranked stocks also have favorable Style Scores for potential upside [10] Company Spotlight: Tyler Technologies - Tyler Technologies is a leading provider of integrated information-management solutions for the public sector, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of B [12] - The company is projected to experience a year-over-year earnings growth of 19.5% for the current fiscal year, supported by a Growth Style Score of A [12] - Recent upward revisions in earnings estimates have led to a Zacks Consensus Estimate of $11.41 per share, with an average earnings surprise of +4.3%, making Tyler Technologies a strong candidate for investors [13]

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Recent Price Strength Screen - The "Recent Price Strength" screen is a unique short-term trading strategy that helps identify stocks with strong fundamentals capable of maintaining an uptrend [2]. - Stocks that pass this screen are typically trading in the upper portion of their 52-week high-low range, indicating bullish sentiment [2]. Group 2: Intellicheck Mobilisa, Inc. (IDN) - Intellicheck Mobilisa, Inc. (IDN) has shown a solid price increase of 32.2% over the past 12 weeks, indicating investor confidence in its potential upside [3]. - IDN has maintained a price increase of 2.7% over the last four weeks, suggesting that the upward trend is still intact [4]. - Currently, IDN is trading at 81.2% of its 52-week high-low range, indicating a potential breakout [4]. Group 3: Fundamental Strength - IDN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The Zacks Rank system has a strong track record, with Rank 1 stocks averaging an annual return of +25% since 1988 [6]. - The Average Broker Recommendation for IDN is also 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [6]. Group 4: Additional Investment Opportunities - Besides IDN, there are several other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [7]. - The article mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [7].

Core Viewpoint - Wells Fargo is expected to report an increase in fourth-quarter earnings and revenue compared to the previous year [1] Financial Performance - Analysts anticipate fourth-quarter earnings of $1.67 per share, up from $1.43 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $21.66 billion, an increase from $20.38 billion reported last year [1] Stock Performance - Shares of Wells Fargo rose 0.4% to close at $95.95 [2] Analyst Ratings - TD Cowen analyst maintained a Hold rating and increased the price target from $93 to $102 [3] - Truist Securities analyst maintained a Buy rating and raised the price target from $100 to $104 [3] - Baird analyst downgraded the stock from Neutral to Underperform with a price target of $90 [3] - Barclays analyst maintained an Overweight rating and raised the price target from $94 to $113 [3] - Keefe, Bruyette & Woods analyst maintained a Market Perform rating and increased the price target from $92 to $101 [3]

Core Viewpoint - The average brokerage recommendation (ABR) for CRISPR Therapeutics AG (CRSP) is 1.96, indicating a general suggestion to buy the stock, but reliance solely on this metric may not be advisable due to potential biases in brokerage recommendations [2][5][11]. Brokerage Recommendations - CRISPR Therapeutics has an ABR of 1.96, which is close to a "Strong Buy" rating, based on recommendations from 29 brokerage firms [2]. - Out of the 29 recommendations, 15 are classified as "Strong Buy" and 1 as "Buy," representing 51.7% and 3.5% of total recommendations, respectively [2]. Limitations of Brokerage Recommendations - Brokerage analysts often exhibit a strong positive bias in their ratings due to vested interests, leading to a higher number of "Strong Buy" recommendations compared to "Strong Sell" [6][11]. - Studies indicate that brokerage recommendations may not effectively guide investors toward stocks with the highest potential for price appreciation [5][11]. Zacks Rank Comparison - The Zacks Rank, a proprietary stock rating tool, categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell) and is based on earnings estimate revisions, which are more reliable indicators of near-term stock performance [8][12]. - The Zacks Rank is updated more frequently than the ABR, reflecting timely changes in earnings estimates and business trends [13]. Current Earnings Estimates for CRISPR Therapeutics - The Zacks Consensus Estimate for CRISPR Therapeutics remains unchanged at -$6.34 for the current year, suggesting stable analyst views on the company's earnings prospects [14]. - Due to the unchanged consensus estimate and other factors, CRISPR Therapeutics holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the positive ABR [15].

Group 1 - Bank of America is set to release its fourth-quarter earnings on January 14, with analysts expecting earnings of 96 cents per share, an increase from 82 cents per share in the same period last year [1] - The consensus estimate for Bank of America's quarterly revenue is $27.62 billion, up from $25.35 billion reported in the previous year [1] - On January 7, 2026, TD Cowen analyst Steven Alexopoulos raised the price target for BAC stock from $64 to $66, maintaining a Buy rating [3] Group 2 - Bank of America announced the redemption of $3 billion in fixed/floating rate senior notes due January 2027 [2] - Shares of Bank of America fell 0.6% to close at $55.85 on the day of the announcement [2] - Goldman Sachs analyst Richard Ramsden increased the price target for BAC from $58 to $64 while maintaining a Buy rating on January 6, 2026 [3]

Bank of America (NYSE:BAC) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 14.Analysts expect the bank to report fourth-quarter earnings of 96 cents per share. That's up from 82 cents per share in the year-ago period. The consensus estimate for Bank of America’s quarterly revenue is $27.62 billion (it reported $25.35 billion last year), according to Benzinga Pro.On Friday, Bank of America announced redemption of $3,000,000,000 5.080% fixed/floating rate senior notes, ...

Earnings Report - Citigroup Inc. is set to release its fourth-quarter earnings results on January 14, 2025, before the market opens [1] - Analysts project earnings of $1.62 per share, an increase from $1.35 per share in the same quarter last year [1] - The consensus estimate for quarterly revenue is $20.45 billion, up from $19.58 billion a year earlier [1] Business Operations - On December 29, Citigroup's board approved a plan to sell AO Citibank, completing the exit from its remaining operations in Russia [2] - Following this announcement, Citigroup shares fell by 0.6%, closing at $120.60 [2] Analyst Ratings - Goldman Sachs analyst Richard Ramsden maintained a Buy rating and raised the price target from $113 to $127 [3] - Truist Securities analyst John McDonald also maintained a Buy rating, increasing the price target from $123 to $129 [3] - Wells Fargo analyst Mike Mayo maintained an Overweight rating, raising the price target from $125 to $150 [3] - Barclays analyst Jason Goldberg maintained an Overweight rating, increasing the price target from $115 to $146 [3] - Piper Sandler analyst Scott Siefers maintained an Overweight rating, raising the price target from $120 to $130 [3]

Core Viewpoint - Morgan Stanley analysts have identified Colgate-Palmolive as their top pick in the Household & Personal Care sector, anticipating a recovery in the company's sales growth in 2026 after a disappointing performance in 2025 [2][8] Sales Growth Expectations - Analysts expect Colgate-Palmolive's sales growth to recover in 2026, projecting 3% organic sales growth and 6% earnings per share growth, despite a conservative outlook for the fourth quarter [5][6] - The company experienced a low point in organic sales growth at 0.4% in its last quarterly results, but is expected to outperform competitors in the coming quarters [5] Market Context - The consumer packaged goods sector faced "category weakness" in 2025, which impacted Colgate-Palmolive's performance, alongside challenging comparisons from a strong 2024 [3][4] - Colgate-Palmolive shares fell by double-digit percentages in 2025, but analysts predict a 13% increase in share price this year, aligning with Wall Street's average forecast [4][8] Competitive Position - Factors contributing to the expected recovery include easier comparisons from 2025, growth in developing markets, and a projected recovery in market share within the oral care segment [6][7] - Analysts believe that while individual factors may not be significant, collectively they create a clear path for Colgate-Palmolive to reaccelerate organic sales growth above its peers [7]

Core Insights - High-rolling investors are bullish on Roku, indicating potential privileged information influencing their trading decisions [1] - The sentiment among major traders is split, with 33% bullish and 33% bearish, highlighting mixed market expectations [2] Options Activity - A total of 9 options trades for Roku were identified, with 8 calls totaling $406,242 and 1 put amounting to $27,411, suggesting a stronger interest in calls [2] - Whales have targeted a price range for Roku between $55.0 and $120.0 over the last 3 months, indicating significant price movement expectations [3] - The average open interest for Roku options is 346.78, with total volume reaching 429.00, reflecting active trading in the options market [4] Company Overview - Roku enables streaming for over 90 million households, providing 127 billion streaming hours in 2024, making it the leading streaming operating system in the US [8] - Revenue is generated primarily from device sales, licensing, advertising, and subscription fees from platforms sold through Roku [8] Market Status - Roku's current trading volume is 1,564,184, with a price increase of 1.25% to $111.68, and analysts suggest the stock may be approaching overbought conditions [11] - Analyst ratings show a consensus target price of $133.4, with several analysts upgrading their ratings and price targets, indicating positive market sentiment [10][12]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [2] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score identifies attractive stocks using ratios like P/E, PEG, and Price/Sales, focusing on stocks that are undervalued [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook, focusing on earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends, using metrics like price changes and earnings estimate revisions to identify optimal entry points [5] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive rating to identify stocks with the best overall potential [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.9% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [10] - Stocks with a 3 (Hold) rank should also have A or B Scores to ensure potential upside [10] Company Spotlight: Casey's General Stores - Casey's General Stores operates approximately 2,921 convenience stores across 19 states, primarily in Iowa, Missouri, and Illinois [12] - The company holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong investment potential [12] - Forecasts suggest an 18% year-over-year earnings growth for the current fiscal year, with upward revisions in earnings estimates [13]